Navigation Links
SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
Date:10/15/2008

SAN FRANCISCO, Oct. 15 /PRNewswire/ -- SourceSolution, a leader in search technology for the biotechnology and pharmaceutical industries, announced today that it is on target to launch a new initiative next month, which reduces the time and cost of screening contract manufacturing and research organizations (CMOs/CROs). The proprietary technology will be offered to customers as a Software as a Service (SaaS) database. The database will allow users to perform detailed searches of service provider capabilities against customizable project requirements.

The web-based platform will simplify the initial screening process for both buyers and service providers. Currently, biotechnology and pharmaceutical companies have limited tools at their disposal to efficiently evaluate CMO/CRO capabilities. Limited tools force many of these companies to engage in a cumbersome and time-consuming exchange of data in RFIs or RFPs. SourceSolution users may select standardized capability and regulatory criteria in searches for contract providers. CMOs and CROs will update and maintain these profiles to ensure that all potential clients are accessing information that is current and accurate. Effective initial screening will reduce expenses that would be incurred when there is an incomplete understanding of project requirements and capabilities for both parties. Once a buyer identifies a number of CMOs/CROs for further evaluation, the service providers will be notified that their capabilities have matched with potential projects and will be provided with a qualified sales lead for follow-up.

The initiative will be launched in November prior to the American Association of Pharmaceutical Scientists (AAPS) annual meeting in Atlanta, Georgia. As part of the launch, SourceSolution will be offering a number of free webinars in October and November. More information can be found by visiting http://www.s
'/>"/>

SOURCE SourceSolution, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
2. Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler
3. AMDL, Inc. Announces Strategic Realignment
4. Sysmex Announces Clinical Laboratory Software Name Change
5. Mirixa Announces Agreement With the Pharmacy Guild of Australia
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
8. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
9. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
10. CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved
11. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10